menu
    • menu
    [{"orgOrder":0,"company":"Kindeva Drug Delivery","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Salbutamol Sulphate","moa":"ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Kindeva Drug Delivery","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation aerosol","sponsorNew":"Kindeva Drug Delivery \/ Sandoz","highestDevelopmentStatusID":"12","companyTruncated":"Kindeva Drug Delivery \/ Sandoz"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Avillion LLP","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Salbutamol Sulphate","moa":"ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation Aerosol","sponsorNew":"AstraZeneca \/ Avillion","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Avillion"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Salbutamol Sulphate","moa":"ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation Aerosol","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Not Applicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Salbutamol Sulphate","moa":"ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation Powder","sponsorNew":"Teva Pharmaceutical Industries \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Teva Pharmaceutical Industries \/ Not Applicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Salbutamol Sulphate","moa":"ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation Powder","sponsorNew":"Teva Pharmaceutical Industries \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Teva Pharmaceutical Industries \/ Not Applicable"},{"orgOrder":0,"company":"Perrigo Company plc","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Salbutamol Sulphate","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Perrigo Company plc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Perrigo Company plc \/ Catalent","highestDevelopmentStatusID":"12","companyTruncated":"Perrigo Company plc \/ Catalent"},{"orgOrder":0,"company":"Avillion LLP","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Salbutamol Sulphate","moa":"ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Avillion LLP","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation Aerosol","sponsorNew":"Avillion LLP \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Avillion LLP \/ AstraZeneca"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Salbutamol Sulphate","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation Powder","sponsorNew":"Teva Pharmaceutical Industries \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Teva Pharmaceutical Industries \/ Not Applicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Salbutamol Sulphate","moa":"ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Teva Pharmaceutical Industries \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Teva Pharmaceutical Industries \/ Not Applicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Avillion LLP","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Salbutamol Sulphate","moa":"ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation Aerosol","sponsorNew":"AstraZeneca \/ Avillion LLP","highestDevelopmentStatusID":"12","companyTruncated":"AstraZeneca \/ Avillion LLP"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Avillion LLP","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Salbutamol Sulphate","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Aerosol (PMDI)","sponsorNew":"AstraZeneca \/ Avillion LLP","highestDevelopmentStatusID":"12","companyTruncated":"AstraZeneca \/ Avillion LLP"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Salbutamol Sulphate","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Aerosol (PMDI)","sponsorNew":"Amneal Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amneal Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Salbutamol Sulphate","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Aerosol (PMDI)","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZeneca \/ Not Applicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Launch Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Fluticasone Propionate","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Teva Pharmaceutical Industries \/ Launch Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Teva Pharmaceutical Industries \/ Launch Therapeutics"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Abingworth","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2024","type":"Financing","leadProduct":"Fluticasone Propionate","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Teva Pharmaceutical Industries","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.14999999999999999,"dosageForm":"Powder for Inhalation","sponsorNew":"Teva Pharmaceutical Industries \/ Abingworth","highestDevelopmentStatusID":"6","companyTruncated":"Teva Pharmaceutical Industries \/ Abingworth"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Albuterol Sulfate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"AstraZeneca \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Salbutamol Sulphate

    Menu

    Salbutamol Sulphate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            AstraZeneca

                            United Kingdom arrow
                            American Pharma Summit
                            Not Confirmed

                            AstraZeneca

                            United Kingdom arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Salbutamol Sulphate,Budesonide

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Airsupra Demonstrates Significant Reduction in Severe Exacerbations in Asthma Patients

                            Details : Airsupra (albuterol/budesonide) formerly known as PT027, is a first-in-class SABA/ICS. It is being investigated in patients with intermittent or mild persistent asthma.

                            Brand Name : Airsupra

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 07, 2024

                            Lead Product(s) : Salbutamol Sulphate,Budesonide

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Teva Pharmaceutical Industries

                            Israel arrow
                            American Pharma Summit
                            Not Confirmed

                            Teva Pharmaceutical Industries

                            Israel arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fluticasone Propionate,Salbutamol Sulphate

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase I

                            Sponsor : Launch Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Teva And Launch Therapeutics Collaborates For Dual-Action Asthma Rescue Inhaler Program

                            Details : The collaboration aims to further accelerate the clinical research program of Teva’s ICS-SABA (TEV-56248), albuterol/fluticasone combination, currently in Phase 3 clinical trials for asthma.

                            Brand Name : TEV-56248

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            April 01, 2024

                            Lead Product(s) : Fluticasone Propionate,Salbutamol Sulphate

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase I

                            Sponsor : Launch Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Teva Pharmaceutical Industries

                            Israel arrow
                            American Pharma Summit
                            Not Confirmed

                            Teva Pharmaceutical Industries

                            Israel arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fluticasone Propionate,Salbutamol Sulphate

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase I

                            Sponsor : Abingworth

                            Deal Size : $150.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Teva, Launch Therapeutics Partner for Dual-Action Asthma Inhaler Development

                            Details : The net proceeds will be used to further accelerate the clinical research program of Teva’s ICS-SABA (TEV-56248), albuterol/fluticasone combination, currently in Phase 3 clinical trials for asthma.

                            Brand Name : TEV-56248

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            April 01, 2024

                            Lead Product(s) : Fluticasone Propionate,Salbutamol Sulphate

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase I

                            Sponsor : Abingworth

                            Deal Size : $150.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            AstraZeneca

                            United Kingdom arrow
                            American Pharma Summit
                            Not Confirmed

                            AstraZeneca

                            United Kingdom arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Salbutamol Sulphate,Budesonide

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Airsupra Now Available as FDA-Approved Anti-Inflammatory Asthma Rescue Option

                            Details : Airsupra (albuterol/budesonide) formerly known as PT027, is a first-in-class SABA/ICS. It is now available as the first and only FDA-approved anti-inflammatory rescue option for asthma.

                            Brand Name : Airsupra

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 22, 2024

                            Lead Product(s) : Salbutamol Sulphate,Budesonide

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Amneal Pharmaceuticals

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed

                            Amneal Pharmaceuticals

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Salbutamol Sulphate

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Amneal Submits Abbreviated New Drug Applications to U.S. FDA for Three Key Complex Generics

                            Details : Albuterol sulfate inhalation powder is first and only breath-actuated, digital SABA inhaler, which is used for prevention of bronchospasm related to exercise-induced or reversible obstructive airway disease.

                            Brand Name : Proair HFA-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 26, 2023

                            Lead Product(s) : Salbutamol Sulphate

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            AstraZeneca

                            United Kingdom arrow
                            American Pharma Summit
                            Not Confirmed

                            AstraZeneca

                            United Kingdom arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Salbutamol Sulphate,Budesonide

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Approved

                            Sponsor : Avillion LLP

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Airsupra (PT027) Approved in the US for Asthma

                            Details : Airsupra (albuterol/budesonide), is a first-in-class SABA/ICS rescue treatment for asthma in the US. It is an inhaled, fixed-dose combination of albuterol, a SABA, and budesonide, and has been developed in a pMDI using AstraZeneca’s Aerosphere delivery...

                            Brand Name : Airsupra

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 11, 2023

                            Lead Product(s) : Salbutamol Sulphate,Budesonide

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Approved

                            Sponsor : Avillion LLP

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            AstraZeneca

                            United Kingdom arrow
                            American Pharma Summit
                            Not Confirmed

                            AstraZeneca

                            United Kingdom arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Salbutamol Sulphate,Budesonide

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase III

                            Sponsor : Avillion LLP

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            PT027 Recommended by FDA Advisory Committee as New Rescue Treatment for Asthma

                            Details : PT027 (albuterol/budesonide) is a potential first-in-class, pressurised metered-dose inhaler (pMDI), fixed-dose combination rescue medication in the US containing albuterol, a short-acting beta2-agonist (SABA), and budesonide, an anti-inflammatory inhale...

                            Brand Name : PT027

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 09, 2022

                            Lead Product(s) : Salbutamol Sulphate,Budesonide

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase III

                            Sponsor : Avillion LLP

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Teva Pharmaceutical Industries

                            Israel arrow
                            American Pharma Summit
                            Not Confirmed

                            Teva Pharmaceutical Industries

                            Israel arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Salbutamol Sulphate

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            CONNECT1 Study Published in Journal of Allergy and Clinical Immunology: In Practice Evaluates the Potential of...

                            Details : Result showed adults and children aged 13 and older with uncontrolled asthma using ProAir Digihaler (albuterol sulfate) and integrated system had 85.3% higher odds of improving their asthma control after 3 months compared with those using standard-of-car...

                            Brand Name : ProAir Digihaler

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 07, 2022

                            Lead Product(s) : Salbutamol Sulphate

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Teva Pharmaceutical Industries

                            Israel arrow
                            American Pharma Summit
                            Not Confirmed

                            Teva Pharmaceutical Industries

                            Israel arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Salbutamol Sulphate

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Teva to Present First Data Set from the CONNECT1 Clinical Trial on ProAir® Digihaler® (albuterol sulfate) In...

                            Details : Study evaluated the effect of ProAir Digihaler System on asthma control versus standard of care as measured by Asthma Control Test, and explored use of the ProAir Digihaler System to help support patient-physician interactions for asthma management versu...

                            Brand Name : ProAir Digihaler

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 29, 2022

                            Lead Product(s) : Salbutamol Sulphate

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Avillion LLP

                            United Kingdom arrow
                            American Pharma Summit
                            Not Confirmed

                            Avillion LLP

                            United Kingdom arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Salbutamol Sulphate,Budesonide

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase III

                            Sponsor : AstraZeneca

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            US FDA Accepts New Drug Application Filed by Avillion for Astra Zeneca's PT027 For the As-Needed Treatment or ...

                            Details : PT027 (Albuterol Sulfate) is a potential first-in-class inhaled, fixed-dose combination of albuterol, a short-acting beta2-agonist (SABA), and budesonide, an inhaled corticosteroid (ICS), in the US, being developed by Avillion and AstraZeneca under an ag...

                            Brand Name : PT027

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 31, 2022

                            Lead Product(s) : Salbutamol Sulphate,Budesonide

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase III

                            Sponsor : AstraZeneca

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth